United States In-Vitro Diagnostics (IVD) Market Growth Opportunities 2017-2021 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Growth Opportunities in the US In Vitro Diagnostics (IVD) Market, Forecast to 2021" report to their offering.

The key objectives of this growth opportunity study are to track the changes in the IVD market landscape in the United States for 2016-2021.

The study aims to identify growth segments and disruptive companies to invest into. Further, the study provides an in-depth revenue and market share analysis of over 8 segments within the IVD landscape: POCT, tissue diagnostics, self-monitoring blood glucose meter (SMBG), hemostasis, hematology, clinical chemistry, microbiology, immunochemistry, and molecular diagnostics.

The study highlights industry challenges, growth drivers, restraints, competitive developments, mergers and acquisition, and investment opportunities. It also discusses the impact of Protecting Access to Medicare Act (PAMA), identifies transforming business models, and makes strategic recommendations to understand the dynamics of the US IVD market. The study also covers key trends and growth opportunities, game-changing companies, disruptive technologies and transforming business models, as well as strategic recommendations.

The In Vitro Diagnostics (IVD) landscape in the United States is extremely dynamic, with a high level of merger and acquisition activity with many high-value deals still pending. Both clinical laboratories and manufacturers are increasingly vying for smaller specialized niche technology companies to increase their market share. Molecular point of care testing (POCT) and liquid biopsy continue to attract investment opportunities from private equity and venture capitalists.

The new government in the United States aims to provide a retail-like experience for healthcare services. As a result, innovative and clinically vetted direct to consumer (DTC) diagnostic testing services are expected to thrive. Partnerships with non-healthcare (HC) companies are expected to empower core diagnostic companies with artificial intelligence (AI) and big data capabilities are on the rise. Given these market trends, it is important to understand the market dynamics to remain competitive and successful in the IVD market in the United States of America.

Key Topics Covered:

1. Executive Dashboard

2. Growth Environment-Market Overview

3. Vision and Strategy-Emerging Growth Opportunities

4. Total Market Forecasts

5. Competitive Analysis

6. Hematology Segment Breakdown

7. Hemostasis Segment Breakdown

8. POCT Segment Breakdown

9. Molecular Diagnostics Segment Breakdown

10. Tissue Diagnostics Segment Breakdown

11. SMBG Segment Breakdown

12. Clinical Microbiology Segment Breakdown

13. Immunochemistry Segment Breakdown (Includes Revenues for Immunossay, Clinical Chemistry, and Urinalysis)

14. Last Word

15. Appendix (Capital Pricing and Installed Base)

Companies Mentioned

- Abbott

- Alere

- Bayer

- Becton Dickinson

- bioMerieux

- BioRad

- Danaher

- LifeScan (JnJ)

- Orthi Clinical

- Roche

- Siemens

- Sysmex

- Thermo Fisher Scientific

For more information about this report visit http://www.researchandmarkets.com/research/6ds8dm/growth

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: In Vitro Diagnostics

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: In Vitro Diagnostics